Curi Bio Inc.

Seattle, WA

UEI
D6VABZ7RVM84
CAGE
7C8Q3
Primary NAICS
334516 Analytical Laboratory Instrument Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
3000 Western Ave, Seattle, WA 98121, USA
Website
curibio.com
Founded
2015
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $0
FY2024 $17,020

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
University Of Washington Enhanced gene therapy for DMD using larger dystrophins and lower vector doses. HT94252310976 $94,332

Similar vendors

About the company

Curi Bio Inc. is a Seattle-based corporate entity registered in SAM.gov as a self-certified small disadvantaged business and manufacturer of goods. The company specializes in developing advanced biomedical research technologies, particularly focusing on cell-based platforms, engineered tissue systems, and innovative research instrumentation. Its primary target markets include drug development, drug safety screening, and disease modeling, with a particular emphasis on creating sophisticated cellular and tissue models using human induced pluripotent stem cells (iPSCs).

Through federal contract awards, Curi Bio Inc. has primarily provided specialized research equipment and media kits to various National Institutes of Health (NIH) agencies. These contracts include purchase orders for 3D IPSC skeletal muscle media kits, CytoStretcher devices, and a Mantarray Magnetometric Analyzer for Engineered Tissue Arrays. The contract awards, ranging from $17,020 to $172,800, have been issued by agencies such as the National Center for Advancing Translational Sciences, National Heart Lung and Blood Institute, National Institute on Drug Abuse, and the National Institute of Diabetes and Digestive and Kidney Diseases. None of these contract awards utilized set-aside designations, and they were primarily focused on providing research equipment and specialized cellular research materials.

Curi Bio Inc.'s federal grant awards demonstrate a strong focus on developing advanced preclinical screening platforms for complex medical research challenges. The company has received grants from the National Center for Advancing Translational Sciences for projects including a high-throughput neuromuscular junction assay for Botox potency screening and a cross-species preclinical platform for Duchenne Muscular Dystrophy research. Additional grants from the National Heart Lung and Blood Institute have supported research on cryopreserving stem cell-derived cardiomyocytes, maturation of cardiac cells, and predictive assessments of cardiotoxicity. The grants, ranging from cooperative agreements to project grants, aim to develop innovative platforms for drug development, therapeutic screening, and understanding complex cellular behaviors. The company has also engaged in a sub-grant award with the University of Washington focused on enhanced gene therapy research.

Quick answers

Is Curi Bio Inc. registered in SAM.gov?

Yes. Curi Bio Inc.'s SAM.gov registration is active through January 6, 2027.

What is Curi Bio Inc.'s CAGE code?

Curi Bio Inc.'s CAGE code is 7C8Q3, and its Unique Entity ID (UEI) is D6VABZ7RVM84.

How much has Curi Bio Inc. received in federal contracts?

Federal contracts obligated $17,020 to Curi Bio Inc. in fiscal years 2023 through 2027.

What is Curi Bio Inc.'s most recent federal award?

Curi Bio Inc.'s most recent federal contract award is 3D ipsc skeletal muscle media kits (75N95024P00504), from National Institute on Drug Abuse (NIH), on September 4, 2024.

On GovTribe

See Curi Bio Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe